Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges
Along with PCI's own robust infrastructure expansions, acquisition furthers CDMO's recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug conjugates.
Article content
Article content
PHILADELPHIA — PCI Pharma Services ('PCI') – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its acquisition of Ajinomoto Althea, Inc. ('Althea'), a US-based sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc. For PCI, the acquisition is a cornerstone of a multi-year investment strategy spanning facilities in the United States and Europe. In the United States, Althea's assets combine with PCI's existing sterile fill-finish and advanced drug delivery operations to form a world-class, large-scale manufacturing hub in San Diego, complete with state-of-the-art large-scale aseptic facilities for prefilled syringes and cartridges. Among other categories, Althea's campus specializes in customized, scalable oligonucleotides and peptides, supporting PCI's existing manufacturing of complex formulations and lyophilization for a broad range of injectables – including nanoparticles, mRNA, MABs, proteins and other biologics.
Article content
Additional information regarding this acquisition is available at a dedicated webpage on PCI's website.
Article content
The acquisition also adds high potent vial filling with lyophilization, expanding PCI's sterile fill-finish capacity and serving as an expedient entrée into the rapidly emerging oncology modality of high potent antibody-drug conjugates (ADCs). In fact, the move places PCI among the few US-based CDMOs capable of filling ADCs – a category the company initially began building toward earlier this year, with a sophisticated new pharmaceutical development lab for potent and non-potent compounds at its manufacturing Center of Excellence in Bedford, NH. The Bedford sterile fill-finish expansion strategy started with a large investment in a purpose-built facility featuring twin lyophilizers and a state-of-the-art large-scale isolator filling line compliant with Annex 1. That facility will be GMP ready this summer; since the plant's 2022 groundbreaking, PCI has methodically developed aseptic-by-design processes as part of its commitment to providing fully isolated high-volume vial filling and lyophilization solutions.
Considering this, the acquisition is a natural next step in PCI's evolution in advanced drug delivery systems like prefilled syringes, cartridges and autoinjectors. Last year, PCI announced investments exceeding $365 million to support the clinical- and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced delivery systems, with an emphasis on injectable formats. Comprising new and expanded infrastructure in both the United States and Europe, the effort bolsters PCI's ability to manage the full lifespan of DDCs, from sterile drug product development and manufacturing through clinical trial supply, product launch and commercialization.
Article content
In the United States, the investment includes two new large-scale facilities at PCI's Rockford, Illinois campus. Building upon the company's successful Philadelphia Biotech Center of Excellence, the facilities will house over 25 dedicated suites with high-speed, multiformat lines for clinical- and commercial-scale assembly and packaging of prefilled syringes, autoinjectors, vials and pen-cartridge combinations, and incorporate extensive ISO-standard product testing capabilities and premium top-load cartoning technology. The campus also comprises capabilities for low- to medium-volume DDC assembly and packaging. Both facilities will be GMP ready in fall 2025.
Article content
In Europe, PCI recently acquired a packaging and device assembly facility in Dundalk, Ireland, which provides commercial-scale operations for injectables and oral solid dose products. At its City North Dublin campus, PCI also expanded and constructed a 120,000-sq-ft packaging and device assembly services facility, which is slated to commence operations in summer 2025.
Article content
Elsewhere in Europe, as part of an additional $25 million investment in its Leon, Spain facility, PCI is currently incorporating a sophisticated new high-speed filling line for syringes and cartridges. Equipped with isolator technology, the automated line delivers unsurpassed flexibility and reliability for biopharma customers. The effort also includes a recently completed state-of-the-art biologics development lab, further enhancing PCI's upstream capabilities.
Article content
Assisted by the Althea acquisition, PCI's goal is to be among the first CDMOs to bring the whole lifespan of advanced drug delivery and drug-device combination products under one corporate roof – a journey spanning PCI's clinical trial supply network with cold chain storage solutions straight through launch and commercialization.
Article content
'Our pharma customers and the healthcare personnel and patients they serve are the heartbeat behind each stride we've made throughout this ambitious investment plan in sterile fill-finish and advanced drug delivery solutions,' said Salim Haffar, CEO of PCI Pharma Services. 'Concerning this latest step, Ajinomoto Althea enjoys a longstanding, well-earned reputation for producing novel biologics in various injectable formats. Welcoming Althea's talented professionals into the PCI family strengthens our commitment to turnkey customer partnerships and, ultimately, our dedication to helping improve patient outcomes through life-changing therapies.'
Article content
PCI is a world-leading CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products' speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 35 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 8,000 employees working to bring life-changing therapies to patients.
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
U.S.-EU trade deal raises questions of how Canada will fair as deadline looms
Watch Japan and the EU have now inked trade deals with the U.S., but how will Canada fair as Trump's deadline looms? CTV's Jeremie Charron has more.
CBC
3 hours ago
- CBC
Trump, EU reach trade deal framework
U.S. President Donald Trump and European Commission President Ursula von der Leyen announced the framework of a new trade deal that includes a 15 per cent tariff on most EU imports.
Calgary Herald
5 hours ago
- Calgary Herald
US, China negotiators meet in Stockholm to extend trade truce
Article content While China has denied its responsibility for the flow of the deadly drug, last month it tightened controls over two chemicals that can be used to make the opioid. Earlier this month, Trump praised those moves. 'China has been helping out,' he told reporters. 'We're talking to them and they're making big steps.' Article content For the US, the recent Chinese actions aren't enough, as such moves were required to comply with United Nations measures, according to a person familiar with the trade talks. Chances of reducing the 20% tariff in this round of talks are very slim, added the person who asked not to be identified discussing sensitive matters, while noting everything could change on Trump's whim. Article content China would be willing to cooperate more on fentanyl, said Sun Chenghao, a professor at Tsinghua University in Beijing. But the US would have to remove the related tariffs, stop blaming Beijing for what it sees as a US domestic problem and provide concrete evidence of crimes, he said. Article content Article content The US business community remains hopeful for progress, with Sean Stein, president of the US-China Business Council, telling Bloomberg TV that movement on fentanyl presents the 'biggest opportunity' in talks. Article content 'That then lowers tariffs on the US side, which then opens the door for China to lower tariffs that lets us sell agriculture, lets us sell airplanes, lets us sell automobiles, that let's us sell energy,' he said. Article content Oil Purchases Article content In his comments announcing the talks, Bessent indicated negotiations can now take on a broader array of topics, potentially including Beijing's continued purchases of sanctioned oil from Russia and Iran. Article content Chinese state media has already pushed back against that idea. 'China won't play along' with such attempts to use China to kill Russia's economy, Lv Xiang, a US expert with the Chinese Academy of Social Sciences last week told the state-run tabloid Global Times. Article content Article content By contrast, China's imports of three major energy products from the US hit almost zero in June, marking the first time in almost three years the Asian nation didn't import any crude oil from its top rival. Deliveries of American crude oil, liquefied natural gas and coal have been subject to Chinese tariffs of 10% to 15% since February. Article content Xi's government has begun rolling back some of its other retaliatory measures since the two sides met last month in London. Crucially, Beijing has boosted shipments of rare earth magnets, while the US relaxed restrictions on sales of less-advanced semiconductors to China. Article content In another potential goodwill gesture, as the Sweden talks were announced this month, China revealed it had suspended an antitrust investigation into the local unit of US chemical manufacturer DuPont de Nemours Inc.
